Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Physicians who Treat Acne (US)

Articles with lock require a subscription to GLG News | Request a free trial
Sunil DhawanNovember 19, 2007
CRx-191 - an intriguing combination product
Analysis of: CombinatoRx Announces Initiation of Phase 2a Clinical Study of CRx-191 in Psoriasis | www.pipelinereview.com
Author: Sunil Dhawan, Clinical Assistant Professor of Dermatology, Stanford University
CombinatoRx new combination product- CRx-191 is intriguing in that it combines a topical steroid with nortryptiline to minimize the negative effects of the steroid and make it more potent. This would be useful in that higher potency topical steroids are more effective, but cause more thinning of the...
November 16, 2007
Watch out Tomo....here comes some competition
Analysis of: Varian's New Rapid Arc Delivery | www.varian.com
Author: GLG Expert Contributor
Varian and Elekta's new arc treatments improve workflow, efficiency, and give radiation oncologists a better alternative to tomotherapy.    
Sunil DhawanNovember 12, 2007
Stifel and Allergan collaboration very positive
Analysis of: Stiefel Laboratories, Inc. Enters into Strategic Collaboration with Allergan, Inc. to Expand and Strengthen Dermatologic Product Offering | www.pipelinereview.com
Author: Sunil Dhawan, Clinical Assistant Professor of Dermatology, Stanford University
The recently announced collaboartion between Stiefel and Allergan in regards to Tazorac is very positive. Stiefel needs this molecule to put into different dosage forms, and in combination with its existing products espoecially Duac, etc. Their current acne product line is strong, but this will solodify...
November 8, 2007
me too drug!
Analysis of: A.T.S. Pharmaceuticals, A Division Of Auriga Laboratories, Launches Coraz™ Lotion For The Treatment Of Seborrheic Dermatitis | www.medicalnewstoday.com
Author: GLG Expert Contributor
Why bother with this branded 2% hydrocortisone lotion?  Likely third tier, and nothing special other than the gimicky wash that goes along with it.  The lotion is a very weak %of steroid- so probably minimally useful. ? pediatric indication, would possibly have some hope for the product.
October 26, 2007
Let's all exhale
Analysis of: Pfizer Abandons Exubera, Posts 77% Earnings Decline | online.wsj.com
Author: GLG Expert Contributor
This is a big hit for Pfizer - a costly product they licensed due to lack of good pipeline products.   Unfortunatley, I don't think they anticipated the issues surrounding the complexity of inhaled insulin, properly marketed the product, or did enough research on the patient side (ie compliane,...
October 26, 2007
Cardiovascular risks no laughing matter
Analysis of: More Prominence Urged for Heart Risks in Breast Cancer Treatment | www.medpagetoday.com
Author: GLG Expert Contributor
Cardiovascular disease in breast cancer is a real risk.   As our population is aging, and breast cancer is one of the most comon cancers, it is up to us to minimize risks of treatment related morbidity.
October 26, 2007
Pharmaceutical greed and the fleecing of medicare
Analysis of: Genentech to Limit Avastin Availability | online.wsj.com
Author: GLG Expert Contributor
While the data between avastin and lucentis is pending, it's interesting to see Genetch trying to defending profits at the expense of patients.   Genetech has impeded this trial, so that they could defend sales of Lucentis. Before lucentis was approved, avastin was used for macular degeneration...
October 25, 2007
Initial Avastin data interesting
Analysis of: Avastin seen as helpful against deadly brain tumor | www.reuters.com
Author: GLG Expert Contributor
Glioblastoma multiforme are one of the worst tumors one can have - period.   Even with aggressive surgery, chemotherapy and radiation, most of these patients succumb to their disease within 1 year.   Initial results of Avastin + Irinotecan look promising as a second line regimen.  ...
October 18, 2007
Government Nonsense, Again
Analysis of: Nonpayment for Performance? Medicare's New Reimbursement Rule | content.nejm.org
Author: GLG Expert Contributor
This is an absurdity. 
Sunil DhawanOctober 8, 2007
Abbotts ABT-874 shows good results in Psoriasis
Analysis of: Abbott's ABT-874 Shows Positive Results for Maintenance of Response in Phase II Psoriasis Study | www.pipelinereview.com
Author: Sunil Dhawan, Clinical Assistant Professor of Dermatology, Stanford University
Abbotts ABT-874 monoclonal antibody for psoriasis shows impressive results in the phase 2 trial. The results were up to 90% of patients achieving at least 75% reduction in their psoriasis. These results are as good or better than those with Remicade the most effective biologic for psoriasis currently....

Previous Page : 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 Next71 to 80 of 191

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-01T21:45:56.203